{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:03:17Z","timestamp":1785434597206,"version":"3.56.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["24011102102"],"award-info":[{"award-number":["24011102102"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["25011102121"],"award-info":[{"award-number":["25011102121"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, driven by late-stage diagnosis, metastatic progression, and therapeutic resistance. Src homology region 2 domain-containing phosphatase 2 (SHP2) has emerged as a critical regulator of oncogenic signaling in gastric tumorigenesis, yet its therapeutic targeting remains underexplored. In this study, we evaluated the anti-cancer efficacy of NSC 57774, a novel SHP2 inhibitor, using integrated bioinformatics and functional assays in AGS gastric cancer cells. Analysis of The Cancer Genome Atlas (TCGA) and UALCAN datasets revealed marked upregulation of SHP2 and multiple receptor tyrosine kinases in gastric cancer tissues. NSC 57774 potently inhibited cell proliferation and migration, demonstrating selective cytotoxicity towards cancer cells over non-cancerous fibroblasts. Mechanistically, NSC 57774 disrupted key oncogenic pathways including MAPK\/ERK, AKT and STAT3 in a concentration- and time-dependent manner, with higher doses achieving more sustained pathway suppression. NSC 57774 suppressed NF-\u03baB inflammatory signaling at early timepoints and induced cleaved caspase-3 across all treatment groups at 72 hours, indicative of pro-apoptotic activity. A paradoxical late-phase increase in phospho-p38 was observed at 72 hours, consistent with a compensatory pro-apoptotic stress response. Comparative analysis revealed that NSC 57774 outperformed the commercial SHP2 inhibitor NSC 87877 and doxorubicin in reducing viability and migration of gastric cancer cells. Collectively, these findings position NSC 57774 as a promising candidate for targeted gastric cancer therapy, capable of disrupting multiple signaling pathways involved in tumor progression, metastasis, and inflammation, warranting further preclinical and clinical investigation.<\/jats:p>","DOI":"10.1371\/journal.pone.0354605","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:30:26Z","timestamp":1785432626000},"page":"e0354605","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-1022","authenticated-orcid":true,"given":"Ghalia","family":"Khoder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2465-0812","authenticated-orcid":true,"given":"Rose","family":"Ghemrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Sammani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Harati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibran Sualeh","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Khair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"16","key":"pone.0354605.ref001","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk and prognostic factors of gastric cancer","volume":"29","author":"W-J Yang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"pone.0354605.ref002","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/cancers15030664","article-title":"A global perspective on gastric cancer screening: which concepts are feasible, and when?","volume":"15","author":"W Januszewicz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0354605.ref003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"N Ebrahimi","year":"2023","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"pone.0354605.ref004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/humu.20005","article-title":"Noonan syndrome-associated SHP2\/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2\/MAPK1 activation","volume":"23","author":"A Fragale","year":"2004","journal-title":"Hum Mutat"},{"issue":"25","key":"pone.0354605.ref005","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/bi5002695","article-title":"Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations","volume":"53","author":"Z-H Yu","year":"2014","journal-title":"Biochemistry"},{"key":"pone.0354605.ref006","doi-asserted-by":"crossref","first-page":"216029","DOI":"10.1016\/j.canlet.2022.216029","article-title":"SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity","volume":"555","author":"W Zheng","year":"2023","journal-title":"Cancer Lett"},{"issue":"21","key":"pone.0354605.ref007","doi-asserted-by":"crossref","first-page":"16042","DOI":"10.1074\/jbc.M110.111054","article-title":"Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2\/ERK and JAK\/STAT signal transduction pathways in gastric epithelial cells","volume":"285","author":"IO Lee","year":"2010","journal-title":"J Biol Chem"},{"issue":"17","key":"pone.0354605.ref008","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/cancers13174309","article-title":"SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling","volume":"13","author":"Y Nagamura","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0354605.ref009","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3390\/ijms21082893","article-title":"MAP Kinases Pathways in Gastric Cancer","volume":"21","author":"L Magnelli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"pone.0354605.ref010","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1433","article-title":"Oncogenic mechanisms of the Helicobacter pylori CagA protein","volume":"4","author":"M Hatakeyama","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"pone.0354605.ref011","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/fmb.15.32","article-title":"Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system","volume":"10","author":"S Backert","year":"2015","journal-title":"Future Microbiol"},{"issue":"5555","key":"pone.0354605.ref012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1067147","article-title":"SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein","volume":"295","author":"H Higashi","year":"2002","journal-title":"Science"},{"issue":"4","key":"pone.0354605.ref013","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2005.12.038","article-title":"Influence of EPIYA-repeat polymorphism on the phosphorylation-dependent biological activity of Helicobacter pylori CagA","volume":"130","author":"M Naito","year":"2006","journal-title":"Gastroenterology"},{"issue":"8","key":"pone.0354605.ref014","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.3390\/ijms23084468","article-title":"The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines","volume":"23","author":"R Ghemrawi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"pone.0354605.ref015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: An update to the integrated cancer data analysis platform","volume":"25","author":"DS Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"issue":"15","key":"pone.0354605.ref016","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159930","article-title":"SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy models","volume":"7","author":"RD Watkins","year":"2022","journal-title":"JCI Insight"},{"issue":"9","key":"pone.0354605.ref017","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/2211-5463.12493","article-title":"Off-target inhibition by active site-targeting SHP2 inhibitors","volume":"8","author":"R Tsutsumi","year":"2018","journal-title":"FEBS Open Bio"},{"issue":"7","key":"pone.0354605.ref018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4161\/cbt.24591","article-title":"Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells","volume":"14","author":"D Florou","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"pone.0354605.ref019","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1535-7163.MCT-18-0852","article-title":"SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors","volume":"18","author":"H Lu","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"pone.0354605.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"DL Kerr","year":"2021","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"pone.0354605.ref021","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10637-018-0626-5","article-title":"Inhibition of SHP2 by new compounds induces differential effects on RAS\/RAF\/ERK and PI3K\/AKT pathways in different cancer cell types","volume":"37","author":"CG Vazhappilly","year":"2019","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0354605.ref022","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","article-title":"Signaling pathways and therapeutic interventions in gastric cancer","volume":"7","author":"Z-N Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"pone.0354605.ref023","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"K Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"7517","key":"pone.0354605.ref024","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Network Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"14","key":"pone.0354605.ref025","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-24-3691","article-title":"JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK\/RAS\/MAPK and PD-1 Blockade Therapies","volume":"31","author":"D Kang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0354605.ref026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jphs.2020.06.002","article-title":"Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds","volume":"144","author":"W Guo","year":"2020","journal-title":"J Pharmacol Sci"},{"issue":"17","key":"pone.0354605.ref027","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/cancers13174309","article-title":"SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling","volume":"13","author":"Y Nagamura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pone.0354605.ref028","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.104060.3","article-title":"Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer","volume":"14","author":"Y Zhang","year":"2026","journal-title":"Elife"},{"key":"pone.0354605.ref029","article-title":"An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling","volume":"9","author":"J Han","year":"2020","journal-title":"F1000Res"},{"issue":"3","key":"pone.0354605.ref030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"A Cuadrado","year":"2010","journal-title":"Biochem J"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:30:31Z","timestamp":1785432631000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354605"}},"subtitle":[],"editor":[{"given":"Yung-Hsiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354605","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}